ArticleClinical cancer research : an official journal of the American Association for Cancer Research2014
Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 58 citations in OpenAlex.
- Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.Cancer · 2022Trial
- Review
- ChemoSensitivity Assay Guided Metronomic Chemotherapy Is Safe and Effective for Treating Advanced Pancreatic Cancer.Cancers · 2022Article
- Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells.International journal of molecular sciences · 2022Review
- Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma.Genome medicine · 2021Article
- Pancreas cancer: Therapeutic trials in metastatic disease.Journal of surgical oncology · 2021Review
- Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?Cancers · 2021Review
- The implication of liquid biopsies to predict chemoresistance in pancreatic cancer.Cancer drug resistance (Alhambra, Calif.) · 2021Review
- Single Cell Transcriptome in Colorectal Cancer-Current Updates on Its Application in Metastasis, Chemoresistance and the Roles of Circulating Tumor Cells.Frontiers in pharmacology · 2020Review
- Baseline circulating stem-like cells predict survival in patients with metastatic breast Cancer.BMC cancer · 2019Observational
- Review
- The propensity of invasive circulating tumor cells (iCTCs) in metastatic progression and therapeutic responsiveness.Cancer medicine · 2019Article
- Article
- Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases?World journal of gastrointestinal oncology · 2018Article
- Liquid biopsy in pancreatic cancer: the beginning of a new era.Oncotarget · 2018Review
- Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Review
- A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients.Journal of gastrointestinal oncology · 2017Article
- Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems.Medical oncology (Northwood, London, England) · 2017Review
- Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
purposeDespite a challenging prognosis, modern cytotoxic therapy can induce tumor responses and extend life in pancreatic adenocarcinoma (PDAC). Pharmacogenomic (PGx) modeling of tumor tissue can predict the efficacy of chemotherapeutic agents in preclinical cancer models. We hypothesized that PGx profiling of circulating tumor and invasive cells (CTIC) isolated from peripheral blood could predict tumor response, progression, and resistance. EXPERIMENTAL
designA PGx model was created and validated in preclinical models. A prospective clinical trial was conducted. Fifty patients with advanced PDAC were enrolled. Before treatment, 10 mL of peripherally drawn blood was collected. CTICs isolated from this blood sample were expression profiled and the PGx model was used to predict effective and ineffective chemotherapeutic agents. The treating physicians were blinded to PGx prediction.
resultsWe found that CTICs could be reliably isolated, total RNA extracted and profiled from 10 mL of peripheral blood from patients with unresectable PDAC before chemotherapy treatment and at disease progression. Using previously created PGx models to predict chemotherapy sensitivity, we found that clinical benefit was seen for study participants treated with chemotherapy regimens predicted to be effective versus chemotherapy regimens predicted to be ineffective with regard to progression-free (10.4 mo vs. 3.6 mo; P < 0.0001; HR, 0.14) and overall survival (17.2 mo vs. 8.3 mo; P < 0.0249; HR, 0.29).
conclusionsThese findings suggest that PGx profiling of CTICs can predict treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.